ONL Therapeutics
ONL Therapeutics is a clinical-stage biopharmaceutical company developing treatments that protect retinal cells from inflammatory and cell-death pathways. Its lead program is xelafaslatide, formerly ONL1204.
Key facts
| Company Operating Status | Active |
|---|---|
| Full Address | 524 S Main St, Suite 110, Ann Arbor, Michigan 48104, US |
| Public/Private | Private |
| Wellfound ID | onl-therapeutics |